Terminated PHASE4 INTERVENTIONAL 2-arm NCT02275481

A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects

A Comparative Effectiveness and Safety Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects

Sponsor: Sumitomo Pharma America, Inc.

Conditions Chronic Obstructive Pulmonary Disease (COPD)

Interventions Arformoterol tartrate inhalation solution Tiotropium

Updated 12 times since 2017 Last updated: Jun 1, 2018 Started: Nov 30, 2014 Primary completion: Sep 14, 2016 Completion: Sep 14, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

lack of enrollment

Other terminated trials from Sumitomo Pharma America, Inc.

More terminations from Sumitomo Pharma America, Inc.

Other Chronic Obstructive Pulmonary Disease (COPD) trials with similar outcome

Browse all Chronic Obstructive Pulmonary Disease (COPD) trials

Listed as NCT02275481, this PHASE4 trial focuses on Chronic Obstructive Pulmonary Disease (COPD) and remains terminated or withdrawn. Sponsored by Sumitomo Pharma America, Inc., it has been updated 12 times since 2014, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

12 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE4
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE4
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE4
Sep 2023 — Jul 2024 [monthly]

Terminated PHASE4
Dec 2021 — Sep 2023 [monthly]

Terminated PHASE4

▶ Show 7 earlier versions

Jan 2021 — Dec 2021 [monthly]

Terminated PHASE4
Jul 2018 — Jan 2021 [monthly]

Terminated PHASE4
Jun 2018 — Jul 2018 [monthly]

Terminated PHASE4
Oct 2017 — Jun 2018 [monthly]

Terminated PHASE4
Aug 2017 — Oct 2017 [monthly]

Terminated PHASE4
Feb 2017 — Aug 2017 [monthly]

Terminated PHASE4
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE4

First recorded

Nov 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sumitomo Pharma America, Inc.

Data source: Sumitomo Pharma America, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Birmingham, United States , Boston, United States , Buffalo, United States , Cincinnati, United States , Columbus, United States , Flagstaff, United States , Gainesville, United States , Gastonia, United States , Greenville, United States and 17 more locations